Начало >> Статьи >> Литература >> Инсулинотерапия сахарного диабета при беременности

Ссылки - Инсулинотерапия сахарного диабета при беременности

Инсулинотерапия сахарного диабета при беременности
Обоснование инсулинотерапии сахарного диабета
Лечение диабета во время беременности
Применение инсулина во время беременности
Человеческие инсулины
Аналоги инсулина
Аналоги инсулина длительного действия
Изменение потребности в инсулине во время беременности
Инсулинотерапия и беременность


  1. Clinical Guidelines Task Force, International Diabetes Federation. Global Guideline for Type 2 Diabetes, 2005 (www.idf.org; last accessed 30 April 2008).
  2. Confidential Enquiry into Maternal and Child Health. Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland. СЕМАСН: London, 2007.
  3. Hawthorne G, Robson S, Ryall EA, et al. Prospective population based survey of outcome of pregnancy in diabetic women: results of the Northern Diabetic Pregnancy Audit, 1994. BMJ 1997; 315: 279-281.
  4. Jensen DM, Damm P, Moelsted-Pederson L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004; 27: 2819-2823.
  5. Penney GC, Mair G, Pearson DWM, et al. Outcomes of pregnancies in women with type 1 diabetes in Scotland: a national population-based study. Br J Obstet Gynaecol 2003; 110: 315-318.
  6. Evers IM, de Valk HW, Visser GHA. Risk of complications or pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328: 915-918.
  7. Casson IF, Clarke CA, Howard CV, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315: 275-278.
  8. Yang J, Cummings EA, O'Connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol 2006; 108: 644-650.
  9. Macintosh MCM, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006; 333: 177-180.
  10. Diabetes and Pregnancy Group, France. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003; 26:2990-2993.
  11. Piatt MJ, Stanisstreet M, Casson IF, et al. St Vincent's declaration 10 years on: outcomes of diabetic pregnancies. Diabet Med 2002; 19: 216-220.
  12. Confidential Enquiry into Maternal and Child Health. Pregnancy in Women with Type 1 and Type 2 Diabetes, 2003-2003, England, Wales and Northern Ireland. СЕМАСН: London, 2005.
  13. Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med 2005; 10:333-339.
  14. Clausen TD, Mathiesen ER, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-328.
  15. Leinonen PJ, Hiilesmaa VK, Kaaja RJ, Teramo KA. Maternal mortality in type 1 diabetes. Diabetes Care 2001; 24:1501-1502.
  16. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004; 27 (Suppl 1): S88-S90.
  17. Department of Health. National Service Framework for Diabetes: Standards. London: Department of Health, 2001.
  18. Crowther CA, Hilier JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New Engl J Med 2005; 352: 2477-2486.
  19. O'Sullivan J. The Boston gestational diabetes studies. In: HW Sutherland, JM Stowers and DWM Pearson, eds. Carbohydrate Metabolism in Pregnancy and the Newborn. London: Springer-Verlag; 1989:287-294.
  20. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Geneva: World Health Oraanization. 1999. nancies in women with type 1 diabetes. Diabetes Care 2006; 29: 2612-2616.
  21. Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mel- litus: systematic review of observational studies. BMC Pregnancy and Childbirth 2006; 6: 30: doi:10.1186/1471-2393-6-30.
  22. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
  23. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformatio rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988; 318: 671-676.
  24. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care 2007; 30:467-470.
  25. HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet 2002; 78:69-77.
  26. Hampton T. Study finds newborn outcomes affected by blood glucose levels during pregnancy. JAMA 2007; 298:613-614.
  27. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA 1991; 265: 731 -736.
  28. Gunderson EP. Gestational diabetes and nutritional recommendations. Curr Diab Rep 2004; 4: 377-386.
  29. Jovanovic-Peterson L, Peterson CM. Exercise and the nutritional management of diabetes during pregnancy. Obstet Gynecol Clin North Am 1996; 23:75-86.
  30. Turok DK, Ratcliffe SD, Baxley EG. Management of gestational diabetes mellitus. Am Fam Physician 2003; 68:1767-1772.
  31. Langer O, Anyaegbunam A, Brustman L, et al. Management of women with one abnormal oral glucose tolerance test value reduces adverse outcome in pregnancy. Am J Obstet Gynecol 1989; 161:593-599.
  32. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25: 959-973.
  33. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989; 161:415-419.
  34. Bung P, Artal R, Khodiguian N, Kjos S. Exercise in gestational diabetes: an optional therapeutic approach? Diabetes 1991; 40 (Suppl 2): 182-185.
  35. Brankston GN, Mitchell BF, Ryan EA, Okun NB. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am J Obstet Gynecol 2004; 190:188-193.
  36. Ramsay JE, Ferrell WR, Crawford L, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab 2002; 87: 4231-4237.
  37. Harris GD, White RD. Diabetes management and exercise in pregnant patients with diabetes. Clin Diab 2005; 23: 165-168.
  38. Wolfe LA, Heenan AP, Bonen A. Aerobic conditioning effects on substrate responses during graded cycling in pregnancy. Can J Physiol Pharmacol 2003; 81: 696-703.
  39. Clapp JF 3rd, Kiess W. Effects of pregnancy and exercise on concentrations of the metabolic markers tumor necrosis factor alpha and leptin. Am J Obstet Gynecol 2000; 182: 300-306.
  40. Joint Formulary Committee. British National Formulary (ed 55). British Medical Association and Royal Pharmaceutical Society of Great Britain: London, March 2008.
  41. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-1138.
  42. Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med 2007; 24: 253-258.
  43. Hellmuth E, Damm P, Moisted- Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507-511.
  44. Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
  45. Homko CJ, Sivan E, Reece AE. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? Treat Endocrinol 2004; 3: 133-139.
  46. Kerssen A, de Valk HW, Visser GHA. Do HbA1 с levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus? Diabetologia 2006; 49: 25-28.
  47. Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diab 2004; 22: 169-172.
  48. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-885.
  49. De Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requirung insulin therapy. N Engl J Med 1995; 333: 1237-1241.
  50. Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003; 189: 507-512.
  51. El-Halwagy HE, Gelbaya ТА, El-wahab MF, et al. The mean third trimester postprandial blood glucose of diabetic pregnant patients and infant birth weight in the Kuwaiti population. Medscape General Medicine 2001; 3(4).
  52. Ben-Haroush A, Yogev Y, Chen R, et al. The postprandial glucose profile in the diabetic pregnancy. Am J Obstet Gynecol 2004; 191: 576-581.
  53. Lawson PM, Champion MC, Canny C, et al. Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and pre- proliferative retinopathy. Br J Ophthalmol 1982; 96: 762-766.
  54. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984; 311: 365-372.
  55. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
  56. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631-637.
  57. Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type 1 diabetic women. Diabetes Care 1992; 15: 1034-1037.
  58. Rosenn BM, Miodovnik M, Holcberg G, et al. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstet Gynecol 1995; 85:417-422.
  59. Evers IM, ter Braak EWMT, de Valk HW, et al. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 2002; 25: 554-559.
  60. Buchanan ТА, Schemmer JK, Freinkel N. Embryotoxic effects of brief maternal insulin-hypoglycemia during organogenesis in the rat. J Clin Invest 1986; 78: 643-649.
  61. Smoak IW, Sadler TW. Embryopathy effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol 1990; 163: 619-624.
  62. Hanson U, Persson B. Epidemiology of pregnancy-induced hypertension and preeclampsia in type 1 (insulin-dependent) diabetic pregnancies in Sweden. Acta Obstet Gynecol Scand 1998; 77:620-624.
  63. Siddiqi T, Rosenn B, Mimouni F, et al. Hypertension during pregnancy in insulin-dependent diabetic women. Obstet Gynecol 1991; 77: 514-519.
  64. Leguizamon GF, Zeff NP, Fernandez A. Hypertension and the pregnancy complicated by diabetes. Curr Diab Rep 2006; 6: 297-304.
  65. Sierra-Laguado J, Garcia RG, Celedon J, et al. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancyinduced hypertension. Am J Hypertens 2007; 20: 437-442.
  66. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003; 88: 2393-2398.
  67. Bartha JL, Romero-Carmona R, Torrejon-Cardoso R, Comino-Delgado R. Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension. Am J Obstet Gynecol 2002; 187: 735-740.
  68. Solomon CG, Seely EW. Hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001; 37: 232-239.
  69. Ferriss JB. The causes of raised blood pressure in insulin-dependent and noninsulin-dependent diabetes. J Hum Hypertens. 1991; 5: 245-254.
  70. Jensen T, Deckert T. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulindependent diabetic patients. Horm Metab Res Suppl 1992; 26: 68-70.
  71. Aoki TT, Grecu EO, Gollapudi GM, et al. Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus. Endocr Pract 1999; 5: 174-178.
  72. Mulec H, Blohme G, Grande B, Bjorck S. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 651-655.
  73. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-depend-
  74. Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic woman with microalbuminuria. Diabetes Care 2001; 24:1739- 1744.
  75. Nielsen LR, Muller C, Damm P, Mathiesen ER. Reduced prevalence of preterm delivery in women with type 1 diabetes and microalbuminuria - possible effect of early antihypertensive treatment during pregnancy. Diabet Med 2006; 23: 426-431.
  76. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16(Suppl 3):155-165.
  77. The MJ. Human insulin: DNA technology's first drug. Am J Hosp Pharm 1989; 46(Suppl 2): S9-S11.
  78. Deckert T. The immunogenicity of new insulins. Diabetes 1985; 34(Suppl 2):94-96.
  79. Chertow BS, Baranetsky NG, Sivitz Wl, et al. The effects of human insulin on antibody formation in pregnant diabetics and their newborns. Obstet Gynecol 1988; 72: 724-728.
  80. Nachum Z, Ben-Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319: 1223-1227.
  81. Roy B, Chou MCY, Field JB. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-479.
  82. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
  83. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed ana-logue of human insulin. Diabetes 1994; 43: 396-402.
  84. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin. Diabetes Care 1999; 22: 1501- 1506.
  85. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
  86. Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab Res Rev 2005; 21: 241-252.
  87. Rosskamp RH, Park G. Long-acting insulin analogues. Diabetes Care 1999; 22(Suppl 2): B109-B113.
  88. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7:73-82.
  89. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
  90. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
  91. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23:639-643.
  92. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J 0bes2004; 28(Suppl 2):S23-S28.
  93. Jovanovic L, llic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22:1422-1427.
  94. Bhattacharyya S, Brown S, Hughes S, Vice PA. Insulin lispro and regular human insulin in pregnancy. Q J Med 2001; 94: 255-260.
  95. Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 115-121.
  96. Diamond TD, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009-1010.
  97. Kitzmiller JL, Main E, Ward B, et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22:874-875.
  98. Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes traeted with insulin lispro during pregnancy. Diabet Med 2005; 22: 803-807.
  99. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776.
  100. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198: 186.e1-7.
  101. Pettit DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003; 26: 183-186.
  102. Klein O, Lynge J, Endahl L, et al. Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 2006; 55(Suppl 1):A76.
  103. Heise T, Nosek L, Biilmann Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614-1620.
  104. Woolderink JM, van Loon AJ, Storms F, et al. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 2005; 28:2594-2595.
  105. Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 2002; 25: 1095-1096.
  106. Di Cianni G, Volpe L, Lencioni C, et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 2005; 28:982-983.
  107. Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007; 114:453-457.
  108. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
  109. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
  110. Roach P, Yue L, Arora V, The Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
  111. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19:393-399.
  112. Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001; 24:1130-1136.
  113. Langer O, Anyaegbunam A, Brustman L, et al. Progestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol 1988; 159: 616-621.
  114. Rayburn W, Piehl E, Lewis E, et al. Changes in insulin therapy during pregnancy. Am J Perinatal 1985; 2: 271-275.
  115. Steel JM, Johnstone FD, Hume R, Mao JH. Insulin requirements during pregnancy in women with type 1 diabetes. Obstet Gynecol 1994; 83: 253- 258.
  116. McManus RM, Ryan EA. Insulin requirements in insulin-dependent and insulin-requiring GDM women during final month of pregnancy. Diabetes Care 1992; 15: 1323-1327.
  117. Potter JM, Reckless JPD, Cullen DR. Subcutaneous continuous insulin infusion and control of blood glucose concentration in diabetics in third trimester of pregnancy. Br Med J 1980; 280: 1099-1101.
  118. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabete Metab 1986; 12:121-129.
  119. Gimenez M, Conget I, Nicolau J, et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A casecontrol study. Acta Diabetol 2007; 44:34-37.
  120. Jovanovic L. Glucose and insulin requirements during labor and delivery: the case for normoglycemia in pregnancies complicated by diabetes. Endocr Pract 2004; 10(Suppl 2): 40-45.
  121. Jovanovic L, Peterson CM. Insulin and glucose requirements during the first stage of labor in insulin-dependent diabetic women. Am J Med 1983; 75:607-612.
  122. Njenga E, Lind T, Taylor R. Five year audit of peripartum blood glucose control in type 1 diabetic patients. Diabet Med 1992; 9: 567-570.
  123. Lean MEJ, Pearson DWM, Sutherland HW. Insulin management during labor and delivery in mothers with diabetes. Diabet Med 1990; 7: 162- 164.
  124. Caplan RH, Pagliara AS, Beguin EA, et al. Constant intravenous insulin infusion during labor and delivery in diabetes mellitus. Diabetes Care 1982; 5:6-10.
  125. Rosenberg VA, Eglinton GS, Rauch ER, et al. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195:1095-1099.
  126. Feldberg D, Dicker D, Samuel N, et al. Intrapartum management of insulindependent diabetes mellitus (IDDM) gestants: a comparative study of
  127. Macintosh МСМ, Fleming KM at al. BMJ 2006; 333: 177-180
  128. Hawthorne G et al. BMJ 1997; 315: 279-281
  129. EversIMetal.BMJ 2004; 328: 915
  130. Jensen DM, Damm P et al. Diabetes Care 2004; 27:2819-2823

« Заболевания печени у беременных   Интенсивная терапия »